SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Coustan-Smith E,Behm FG,Sanchez J,Boyett JM,Hancock ML,Raimondi SC,Rubnitz JE,Rivera GK,Sandlund JT,Pui CH,Campana D. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1997; 351: 550554.
  • 2
    Cave H,van der Werff ten Bosch J,Suciu S,Guidal C,Waterkeyn C,Otten J,Bakkus M,Thielemans K,Grandchamp B,Vilmer E.(for the EORTC). Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998; 339: 591598.
  • 3
    Van Dongen JJM,Seriu T,Panzer-Grümayer ER,Biondi A,Pongers-Willemse MJ,Corral L,Stolz F,Schrappe M,Masera G,Kamps WA,Gadner H,van Wering ER,Ludwig WD,Basso G,de Bruijn MA,Cazzaniga G,Hettinger K,van der Does-van den Berg A,Hop WC,Riehm H,Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 17311738.
  • 4
    Coustan-Smith E,Sancho J,Hancock ML,Boyett JM,Behm FG,Raimondi SC,Sandlund JT,Rivera GK,Rubnitz JE,Ribeiro RC,Pui CH,Campana D. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 26912696.
  • 5
    Dworzak MN,Fröschl G,Printz D,Mann G,Pötschger U,Mühlegger N, et al.(for the Austrian BFM Study Group). Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 19521958.
  • 6
    Björklund E,Mazur J,Söderhäll S,Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003; 17: 138148.
  • 7
    Vidriales MB,Perez JJ,Lopez-Berges MC,Gutierrez N,Ciudad J,Lucio P,Vazquez L,García-Sanz R,del Cañizo MC,Fernández-Calvo J,Ramos F,Rodríguez MJ,Calmuntia MJ,Porwith A,Orfao A,San-Miguel JF. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: Early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 46954700.
  • 8
    Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A. BIOMED-1 concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. Leukemia 2001; 15: 11851192.
  • 9
    Porwit-MacDonald A,Björklund E,Lucio P,van Lochem EG,Mazur J,Parreira A,van den Beemd MW,van Wering ER,Baars E,Gaipa G,Biondi A,Ciudad J,van Dongen JJ,San Miguel JF,Orfao A. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subset in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000; 14: 816825.
  • 10
    Dworzak MN,Fröschl G,Printz D,De Zen L,Gaipa G,Ratei R,Basso G,Biondi A,Ludwig WD,Gadner H. CD99 expression in T-lineage ALL: Implications for flow cytometric detection of minimal residual disease. Leukemia 2004; 18: 703708.
  • 11
    Gaipa G,Basso G,Maglia O,Leoni V,Faini A,Cazzaniga G,Coliva T,Valsecchi MG,Biondi A,Basso G,Biondi A,Ludwig WD,Gadner H.worzak MN;I-BFM-ALL-FCM-MRD Study Group. Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection. Leukemia 2005; 19: 4956.
  • 12
    Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol 1998; 26: 305313.
  • 13
    Campana D,Coustan-Smith E. Detection of minimal residual disease in acute leukaemia by flow cytometry. Cytometry 1999; 38: 139152.
  • 14
    Weir EG,Cowan K,LeBeau P,Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection. Leukemia 1999; 13: 558567.
  • 15
    Veltroni O,De Zen O,Sanzari MC,Maglia O,Dworzak MN,Ratei R,Biondi A,Basso G,Gaipa G;on behalf of the I-BFM-ALL-FCM-MRD-Study Group, on behalf of the I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: Implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003; 11: 12451252.
  • 16
    Baumgarth N,Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000; 243: 7797.
  • 17
    Owens MA,Vall HG,Hurley AA,Wormsley SB. Validation and quality control of immunophenotyping in clinical flow cytometry. J Immunol Methods 2000; 243: 3350.
  • 18
    Ratei R,Karawajew L,Lacombe F,Jagoda K,Del Poeta G,Kraan J,De Santiago M,Kappelmayer J,Björklund E,Ludwig WD,Gratama J,Orfao A;European Working Group of Clinical Cell Analysis (EWGCCA). Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias. Cytometry Part B 2006; 70B: 19.
  • 19
    Lenkei R,Gratama JW,Rothe G,Schmitz G,D'Hautcourt JL,Arekrans A,Mandy F,Marti G. Performance of calibration standards for antigen quantification with flow cytometry. Cytometry 1998; 33: 188196.
  • 20
    Dworzak MN,Stolz F,Fröschl G,Printz D,Henn T,Fischer S,Fleischer C,Haas OA,Fritsch G,Gadner H,Panzer-Grümayer ER. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: A study of five cases controlled by genetic methods. Exp Hematol 1999; 27: 673681.
  • 21
    Lorenzana R,Coustan-Smith E,Antillon F,Ribeiro RC,Campana D. Simple methods for the rapid exchange of flow cytometric data between remote centers. Leukemia 2000; 14: 336337.
  • 22
    Dworzak MN,Panzer-Grumayer ER. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma 2003; 44: 14451455.
  • 23
    Canonico B,Zamai L,Burattini S,Granger V,Mannello F,Gobbi P,Felici C,Falcieri E,Reilly JT,Barnett D,Papa S. Evaluation of leukocyte stabilisation in TransFix(R)-treated blood samples by flow cytometry and transmission electron microscopy. J Immunol Methods 2004; 295: 6778.
  • 24
    Shrout PE,Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psychol Bull 1979; 86: 420428.
  • 25
    Portnoy LG,Watkins MP. Statistical measures of reliability. In: PortnoyLG,WatkinsMP, editors. Foundations of Clinical Research: Applications to Practice. Norwalk, Conn: Appleton and Lange; 1993. pp 505528.
  • 26
    van der Velden VH,Panzer-Grümayer ER,Cazzaniga G,Flohr T,Sutton R,Schrauder A,Basso G,Schrappe M,Wijkhuijs JM,Konrad M,Bartram CR,Masera G,Biondi A,van Dongen JJ. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706713.
  • 27
    Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia 1997; 11: 12661273.
  • 28
    McKenna RW,Washington LT,Aquino DB,Picker LJ,Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color cytometry. Blood 2001; 98: 24982507.
  • 29
    Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823838.